Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II haploidentical family donor peripheral blood stem cell transplantation for myelodysplastic syndrome and acute leukemia
2017-004423-78Phase 2Terminated
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Sep 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thiotepa, treosulfan, fludarabine, cyclophosphamide, mycophenolate mofetil and 3 more in myelodysplastic syndrome (MDS) and Acute Leukaemia, sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Graft-versus-host disease-free, relapse-free survival. Started Sep 2021; status: terminated.
02
Drugs
thiotepatreosulfanfludarabinecyclophosphamidemycophenolate mofetil
03
Conditions
myelodysplastic syndrome (MDS)Acute Leukaemia
Beyond the preview
Go deeper on 2017-004423-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004423-78.